Roya Navekar1, Maryam Rafraf1, Aida Ghaffari1, Mohammad Asghari-Jafarabadi2, Manouchehr Khoshbaten3. 1. a Nutrition Research Center, Department of Community Nutrition, Faculty of Nutrition and Food Science , Tabriz University of Medical Sciences , Tabriz , IRAN. 2. b Department of Road Traffic Injury Research Center, Faculty of Health , Tabriz University of Medical Science , Tabriz , IRAN. 3. c Liver and Gastrointestinal Diseases Research Center , Tabriz University of Medical Sciences , Tabriz , IRAN.
Abstract
OBJECTIVE: Insulin and leptin resistance are important risk factors for non-alcoholic fatty liver disease (NAFLD). There is limited evidence regarding the effects of turmeric on NAFLD. The aim of this study was to investigate the effects of turmeric supplementation on glycemic status and serum leptin levels in patients with NAFLD. METHODS: This double-blind randomized controlled clinical trial was conducted on 46 patients with NAFLD (21males and 25 females) aged 20-60 years old and body mass index (BMI) between 24.9 and 40 kg/m2. The turmeric group (n = 23) was given six turmeric capsules daily for 12 weeks. Each capsule contained 500 mg turmeric powder (6×500 mg). The placebo group (n = 23) was given six placebo capsules daily for the same period. Fasting blood samples, anthropometric measurements, and physical activity levels were collected at the baseline and at the end of the study. Daily dietary intakes also were obtained throughout the study. Data were analyzed by independent t test, paired t test and analysis of covariance. RESULTS: Turmeric consumption decreased serum levels of glucose, insulin, HOMA-IR and leptin (by 1.22, 17.69, 19.48 and 21.33% respectively, p < 0.05 for all) over 12 weeks compared with those variables in the placebo group. Changes in weight, BMI and liver enzymes were not significant compared to the placebo group. CONCLUSIONS:Turmeric supplementation improved glucose indexes and serum leptin levels and may be useful in the control of NAFLD complications.
RCT Entities:
OBJECTIVE: Insulin and leptin resistance are important risk factors for non-alcoholic fatty liver disease (NAFLD). There is limited evidence regarding the effects of turmeric on NAFLD. The aim of this study was to investigate the effects of turmeric supplementation on glycemic status and serum leptin levels in patients with NAFLD. METHODS: This double-blind randomized controlled clinical trial was conducted on 46 patients with NAFLD (21males and 25 females) aged 20-60 years old and body mass index (BMI) between 24.9 and 40 kg/m2. The turmeric group (n = 23) was given six turmeric capsules daily for 12 weeks. Each capsule contained 500 mg turmeric powder (6×500 mg). The placebo group (n = 23) was given six placebo capsules daily for the same period. Fasting blood samples, anthropometric measurements, and physical activity levels were collected at the baseline and at the end of the study. Daily dietary intakes also were obtained throughout the study. Data were analyzed by independent t test, paired t test and analysis of covariance. RESULTS:Turmeric consumption decreased serum levels of glucose, insulin, HOMA-IR and leptin (by 1.22, 17.69, 19.48 and 21.33% respectively, p < 0.05 for all) over 12 weeks compared with those variables in the placebo group. Changes in weight, BMI and liver enzymes were not significant compared to the placebo group. CONCLUSIONS:Turmeric supplementation improved glucose indexes and serum leptin levels and may be useful in the control of NAFLD complications.
Entities:
Keywords:
Non-alcoholic fatty liver disease; body mass index; insulin resistance; leptin; turmeric
Authors: Maite Martínez-Uña; Yaiza López-Mancheño; Carlos Diéguez; Manuel A Fernández-Rojo; Marta G Novelle Journal: Int J Mol Sci Date: 2020-12-09 Impact factor: 5.923
Authors: Oluyemi Komolafe; Elena Buzzetti; Audrey Linden; Lawrence Mj Best; Angela M Madden; Danielle Roberts; Thomas Jg Chase; Dominic Fritche; Suzanne C Freeman; Nicola J Cooper; Alex J Sutton; Elisabeth Jane Milne; Kathy Wright; Chavdar S Pavlov; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy Journal: Cochrane Database Syst Rev Date: 2021-07-19